Chronic and rare disease patients' access to healthcare services during a health crisis: The example of the COVID‐19 pandemic in Turkey by Aktas, Puren
Health Expectations. 2021;1–9. wileyonlinelibrary.com/journal/hex | 1
Received: 3 March 2021 | Revised: 15 June 2021 | Accepted: 4 July 2021
DOI: 10.1111/hex.13321
OR I G I NA L A R T I C L E
Chronic and rare disease patients' access to healthcare
services during a health crisis: The example of the COVID‐19
pandemic in Turkey
Puren Aktas MA, Doctoral Researcher
Department of Politics, School of Social
Sciences, The University of Manchester,
Manchester, UK
Correspondence
Puren Aktas, Department of Politics, School of
Social Sciences, The University of Manchester,




Objective: The restructuring of healthcare provision for the coronavirus disease
2019 (COVID‐19) pandemic caused disruptions in access for patients with chronic
or rare diseases. This study explores the experiences of patients with chronic or rare
diseases in access to healthcare services in Turkey during the COVID‐19 pandemic.
Methods: Semi‐structured interviews were conducted with representatives (n = 10)
of patient organisations (n = 9) based in Istanbul. Thematic analysis with an in-
ductive approach was conducted to analyse the responses obtained through the
interviews.
Results: The lack of clinical information at the beginning of the pandemic caused
fear among patients with chronic or rare diseases. Patients experienced obstacles in
access to healthcare services because of the overcrowding of hospitals with
COVID‐19 patients. Some treatment procedures were cancelled or postponed by
physicians. Of these procedures, some were medically vital for those patients,
leading to or exacerbating further health problems. The most positive measures that
patients identified were where the Social Security Institution introduced regulations
to facilitate access to prescribed medicine for chronic patients. Information
exchange between the doctors and their patients was important to alleviate the
uncertainty and reduce the anxiety among patients.
Discussion: Access problems experienced by patients during the COVID‐19
pandemic were a complex mix of factors including shortages and physical bar-
riers, but also perceptions of barriers. The findings of this study show that patient
organisations can provide insights on disease‐specific experiences and problems
that are very valuable to improve access to healthcare services to achieve the
universal health coverage target. Hence, this study emphasises the inclusion of
patient organisations in decision‐making processes during times of health crises.
Public Contribution: Representatives of patient organisations participated in the
interviews.
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1 | INTRODUCTION
The coronavirus disease 2019 (COVID‐19) pandemic has introduced
challenges for all dimensions of healthcare systems, forcing countries
to restructure the provision of services to meet urgent demands for
preventing the spread of the virus and treating infected individuals.
Hospitals were transformed into pandemic‐oriented hospitals, elec-
tive surgeries were cancelled, or postponed and face‐to‐face con-
sultations were moved to virtual platforms. Many health systems
experienced shortages of medical supplies, most importantly, in-
tensive care unit (ICU) beds and ventilators, causing ethical dilemmas
for health workers such as rationing of limited healthcare
resources.1,2
The shift in resources among healthcare systems has affected
the delivery of clinical services to patients who did not have
COVID‐19.3 It created disruptions in the continuum of care and
delays in diagnosis procedures. Among patients who do not have
COVID‐19, those with chronic diseases and rare diseases are the
most vulnerable because of their complex health conditions and
routine need to access specialised medical services.4,5 Besides, pa-
tients with rare diseases need regular, multidisciplinary consultations
conducted by a board of specialists and complex treatment services.
Even during the regular functioning of healthcare systems, patients
with rare diseases face significant challenges in access to healthcare
services because of their complex healthcare situation, which re-
quires multidisciplinary consultations, extensive screening and
monitoring procedures and expensive treatments.6
During the pandemic, World Health Organization (WHO) sug-
gested that countries identify context‐relevant essential services to
prioritise for continuation, which includes the provision of medica-
tions, supplies and support from healthcare workers for the ongoing
management of chronic diseases.7,8 Identifying the issues that pa-
tients with chronic diseases might face, WHO listed some mod-
ifications to maintain essential services, which are better information
provision to the patients about COVID‐19 and their disease‐specific
conditions, raising awareness about telehealth or online services for
regular monitoring or urgent care for acute exacerbations or dete-
rioration, creation of self‐management and monitoring plans of the
disease, increasing home supplies of medication and stocks of mon-
itoring devices and modification of routine consultations.8
The problems that faced in response to the pandemic have been
exacerbated by the neoliberal policies implemented in Western
countries since the late 1970s.9 Privatisation of welfare services,
cuts in public healthcare spending and divergence from the public
health centralised approach resulted in a reduced ability to respond
effectively to the pandemic.10 To respond to the pandemic's chal-
lenges, Navarro9 suggests the provision of universal health coverage
(UHC) alongside other publicly provided welfare services. The UHC,
by definition, indicates an ideal that ‘all people have access to the
health services they need, when and where they need them, without
financial hardship’.11 However, this aspirational definition overlooks
an unexpected crisis, such as the COVID‐19 pandemic. The
pandemic has introduced complex challenges to healthcare systems,
interrupting citizens' access to healthcare services even in countries
with UHC. These challenges give rise to the question of whether it
is possible to ensure every citizen's access to healthcare services
during an acute pandemic response considering the different needs
and priorities coexisting within the same healthcare system under
resource constraints.
The restructuring of healthcare services involves potential
trade‐offs between ensuring access to healthcare services for every
citizen and meeting the pandemic's requirements by shifting the
provision of expensive and time‐consuming resources such as ICUs.
This study explores patient experiences during the COVID‐19 pan-
demic in Turkey, with a focus on patients with chronic or rare dis-
eases, considering their complex healthcare needs, which require
specialist services. The findings derive from data collected through
nine semi‐structured interviews conducted with 10 participants from
patient organisations (POs) based in Istanbul. Drawing upon studies
of the impact of the pandemic on patients with chronic or rare dis-
eases, this article aims to contribute to the literature discussing the
capacity of Turkey's healthcare system to meet the needs of citizens
with complex healthcare needs as a country that provides UHC.
2 | LITERATURE REVIEW
Concerns about the access of patients without COVID‐19 to
healthcare services sparked a new corpus of research in medicine to
explore the challenges faced by patients with chronic diseases. Ac-
cording to these studies, the pandemic caused obstacles in access to
essential health services because of the shift of resource allocation
to COVID‐19 services, limits on access to essential and nonessential
services and cancellation or postponement of elective sur-
geries.5,12–16 In a study conducted by Halley et al.,12 some patients
and their relatives stated problems in access to essential medical
supplies because of shortages. The inability to access their doctors
not only worsened their health condition but also led to a sense of
feeling neglected by healthcare providers.12 These issues have ne-
gative impacts on patients' health status,12,13 which is also re-
cognised by healthcare professionals.14 Considering their existing
comorbidities, access problems might create life‐threatening chal-
lenges for patients with chronic or rare diseases.
Access problems not only affect patients in need of medical care
but also those seeking a diagnosis or considering undergoing a di-
agnostic procedure for potential health problems.12,15,17,18 Wingrove
et al.18 surveyed organisations under the World Hepatitis Alliance to
explore the impacts of the pandemic on viral hepatitis services and
people living with viral hepatitis across the world. The results reveal
problems in access to testing and to medication because of the clo-
sure of testing facilities, and lack of adequate information to in-
dividuals living with viral hepatitis. Delays in diagnosis cause
concerns among health professionals because of potential increases
in mortality from delayed treatment.19
Individuals with chronic and rare diseases already experience
uncertainties about their health and future, which have been
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aggravated by the pandemic, such as the risk of contracting the in-
fection, not being able to receive the needed care and lack of both
adequate and conflicting information.20 These uncertainties,
combined with social isolation, created new mental health
challenges or worsened existing ones, as demonstrated by previous
research.13,14,21,22
In an effort to deal with problems in delivering face‐to‐face
consultations, healthcare providers in many countries adopted vir-
tual healthcare provision, known as telemedicine.14,23 However, pa-
tients and their relatives are concerned about telemedicine as the
primary method to access healthcare since they believe that it is
insufficient for managing rare diseases considering the patients'
complex healthcare conditions, which require monitoring and ther-
apeutic services that cannot be easily transferred to online plat-
forms.12 Additionally, virtualisation of the healthcare system
exacerbates the risk of widening inequalities in access to healthcare,
especially for individuals with worse health outcomes, considering
the existing gaps in IT access between individuals with different le-
vels of socioeconomic status.24
3 | TURKISH HEALTHCARE SYSTEM AND
ITS RESPONSE TO COVID ‐19
Turkey, as an upper‐middle‐income country,25 introduced UHC in
2003 with a compulsory social health insurance scheme and equal
benefit packages for all citizens. With a distinctive combination of
universalism in financing and marketization in the provision,26
Turkey incentivized private investment in the healthcare sector. In
addition to public healthcare provision with flat‐rate copayments, the
Social Security Institution (SSI) purchases healthcare services from
private providers with floating copayments for hospital visits. Hence,
the Turkish healthcare system has a competitive internal market that
includes both public and private providers.27
Turkey reported the first COVID‐19 case in the country on
11 March 2020, later than most European countries. The relatively
late arrival of the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) virus to Turkey provided the country with an oppor-
tunity to learn from other countries' experiences with preventive
measures. Hence, immediately after the detection of the first case,
Turkey adopted a pandemic‐oriented approach to transforming the
country's healthcare system. Several measures were introduced to
prevent the spread of the virus such as isolations and quarantines if
needed, country‐wide contact tracing and routine follow‐ups of all
contacted patients by their GPs. During this period, Turkey's relative
advantage in addressing the pandemic was the high number of in-
tensive care beds (46 ICU beds per 100,000 individuals)28 compared
to other OECD countries.29 The large‐scale ‘city hospitals’ estab-
lished with a public–private partnership model have been promoted
by the government as the strength of Turkey's healthcare systems
since all rooms in the city hospitals could be converted into ICUs.30
To make the best of this leverage, the Ministry of Health (MoH)
issued a circular on 20 March 2020, stating that ‘all hospitals with at
least two specialists from infectious diseases and clinical micro-
biology, pulmonary medicine or internal medicine, and level 3 in-
tensive care beds qualify as pandemic hospitals’.31 Accordingly, all
public and private hospitals meeting these conditions started to treat
COVID‐19 patients. Additionally, all elective surgeries were can-
celled as recommended by the MoH. To prevent the overload on
physicians, repeat prescription reports were extended by the SSI and
patients were able to receive their medications from pharmacies
without seeing their doctors if a consultation was not necessary.
Despite the relatively high number of ICU beds in Turkey,
Turkey's healthcare system is characterised by the relative scarcity
of medical staff compared to other OECD countries, with 1.9 phy-
sicians and 2.3 nurses per 1000 individuals.32 The scarcity of medical
staff combined with the increasing workload during the pandemic
raised concerns about the well‐being of the medical staff and has
been a point of weakness in Turkey's response to the COVID‐19
pandemic.33
The pandemic‐oriented healthcare services approach raised
concerns among doctors about the health conditions of chronic pa-
tients in Turkey. The Turkish Medical Association emphasised the
risk of increased morbidity for chronic patients caused by delayed
diagnosis and treatment.34 Calling it a ‘cancer pandemic’, physicians
pointed out the risk of an increasing number of late‐diagnosed can-
cer patients.35 They underscored the importance of early diagnosis
and routine treatment procedures for better health outcomes.35,36
These concerns raised by doctors lead to questions about patient
experiences and their access to healthcare services during the pan-
demic. Patient experiences are multifaceted, which are shaped by
disease‐specific conditions and individual circumstances and ex-
acerbated in the cases of complex health situations. To understand
patient access and identify the problems in healthcare systems, ex-
ploration of patient experiences with their narratives is essential.
This study explores patient experiences during the COVID‐19
pandemic in Turkey, with a focus on patients with chronic or rare
diseases considering their complex healthcare needs demanding
specialist services. The findings derive from data collected through
nine semi‐structured interviews conducted with 10 participants from
POs based in Istanbul. Drawing upon studies of the pandemic's im-
pact on patients with chronic or rare diseases, this article aims to
contribute to the literature discussing Turkey's healthcare system
capacity to meet the needs of citizens with complex healthcare si-
tuations as a country that provides universal health coverage.
4 | METHODS
This study uses qualitative methods to explore patients' experiences
of access to healthcare during the COVID‐19 pandemic, as narrated
by the members of the POs based in Istanbul, Turkey. In‐depth semi‐
structured interviews were conducted over Zoom with 10 re-
spondents from 9 POs based in Istanbul between the period No-
vember and December 2020. The interviews were conducted in
Turkish and lasted an average of 30min. They were audio‐recorded
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with the participants' verbal consent and transcribed verbatim.
Ethical approval for this study was granted by the Institutional
Review Board for Research in Social Sciences and Humanities of
Bogazici University (No: 2020‐54).
The author had a prior relationship with all POs before this
study in the context of another research project, but not with all
respondents. The POs included in this study involve patients and
their relatives in its administration. Among the contacts that the
author has, the most active POs that have strong relationships with
patients were selected to demonstrate the diverse experiences of
patients with different chronic diseases. Thus, the purposive sam-
pling method was used to gather enriched data. The author selected
12 POs to include in this study and sent e‐mails to the official e‐mail
addresses of the POs explaining the content of the study and the
patient information sheet attached. Among 12 POs, 2 POs did not
respond to the e‐mails and 1 PO declined to participate. The re-
maining nine POs agreed to participate. Table 1 presents the char-
acteristics of the participating POs and respondents.
The interview transcripts were analysed in Turkish using NVivo
12. The author conducted a thematic analysis to code the data fol-
lowing the process described by Braun and Clarke,37 using an in-
ductive approach, since the process was driven by data. The author
familiarised herself with the interview transcripts, identified ‘pattern
responses’37 and created codes for overarching themes and sub-
themes. Data included in this article were translated from Turkish
into English by the author.
The findings of this study are subject to limitations. First, the
experiences narrated by the participants reflect unique, disease‐
specific health issues. Second, the participants were selected from
POs based in Istanbul; hence, the experiences might change in dif-
ferent cities of Turkey. Lastly, the data may be subjected to selection
bias as the activeness of the POs and their strong network with the
patients were selection criteria of participants. However, this is also
the strength of the study, since it enables the gathering of enriched
information about the diverse issues that patients with chronic or
rare diseases face during the pandemic.
5 | RESULTS
The analysis of the interviews yielded four main themes: Problems in
access to healthcare services; lack of clinical information, uncertainty
and fear; facilitated access to prescribed medicine; and ongoing in-
formal communication with doctors.
5.1 | Problems in access to healthcare services
Almost all participants (9) mentioned problems in access to routine
and emergency health services caused by the prioritisation of
COVID‐19 patients. Two subthemes emerged from the analysis of
the interviews: Overcrowding of hospitals with COVID‐19 patients
and cancelled or postponed diagnosis and treatment.
5.1.1 | Overcrowding of hospitals with COVID‐19
patients
The circular issued by the MoH on 20 March 2020 assigned some
public and private hospitals as ‘pandemic hospitals’.31 Since patients
with chronic and rare disease need speciality services mostly pro-
vided by these hospitals, almost all representatives (9) from POs
were worried about the inability to find isolated hospitals. These
obstacles were aggravated when patients needed to consult some
specialities, such as infectious diseases and pulmonary medicine
consultants who accept COVID‐19 patients, as stated by a
respondent:
Access to infection physicians was quite difficult
at the beginning of the pandemic period. Since
COVID‐19 is an infection that is covered by the in-
fection unit. Those living with HIV are also treated in
the infection unit. So, access to infection physicians
was difficult at the beginning of the pandemic period.
(3, chronic disease, infectious, neither patient nor a
patient relative).
As the quote above shows, some patients with chronic diseases
were not able to consult their doctors, since the physicians were
accepting patients with COVID‐19. In some cases, they were not able
to get an appointment for vital health problems because of the high
number of patients with COVID‐19 at hospitals:
We have a group of patients whose respiratory mus-
cles are paralyzed because of the ALS disease; these
patients need to get a ventilator as soon as possible.
So, they must continue to live with respiration sup-
port. There are two types of it. Either they will have
surgery, a hole will be created in their throat as you
see on me, or they can get respiration support with a
TABLE 1 Characteristics of POs and respondents
ID PO focus Disease type Respondent characteristic
1 Rare Metabolic Patient relative
2 Rare Metabolic Patient
3 Chronic Infectious Neither
4 Rare Metabolic Patient
5 Rare Muscular Patient
6 Chronic Infectious Patient relative
7 Chronic Metabolic Patient
8A & 8B Rare Neurologic Patient & neither
9 Chronic Metabolic Neither
Abbreviation: PO, patient organisation.
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mask before this surgery. To get this, our patients
need to have a sleep test at night. Our patients could
not get an appointment for this test due to the density
of the pandemic.
(8A, rare disease, neurologic, patient).
Despite the widespread concern about the lack of hospitals
isolated from COVID‐19, some patients found services more acces-
sible due to their age group:
Because the majority of our group, especially the MPS
group, are paediatric patients. In hospitals, as you
know, paediatrics departments are cleaner than oth-
ers, so we can say that they are luckier about that.
(1, rare disease, metabolic, patient relative).
This respondent shares the experience on some patients' in-
ability to access health services when the specialities they have to
consult have fewer COVID‐19 patients. The above quote does not
imply that paediatrics departments were risk‐free in terms of con-
tacting COVID‐19, but instead that these patients' relatives felt safer
about the risk concerning their children, than other patients and
their relatives. Additionally, some physicians and hospitals took
measures to provide services to their patients in an isolated en-
vironment. However, these measures were not enough to relieve the
concerns of patients with chronic or rare diseases about their safety
from COVID‐19:
Usually, they tried to isolate the oncology department,
I mean, I can't say any negative thing about the hos-
pitals on that, they tried to make a separate entrance.
But no matter what, the doctors are constantly in
touch with other patients at hospitals.
(9, chronic, cancer, neither patient nor a patient
relative).
Since COVID‐19 is a communicable disease, some patients were
still worried about their health despite isolated departments at
hospitals. The concern shared by Participant 9 is legitimate con-
sidering the vulnerable health status of cancer patients under
treatment.
5.1.2 | Cancelled or postponed diagnosis and
treatment
Overcrowding of hospitals with COVID‐19 patients resulted in
cancellation or postponement of some diagnosis and treatment
procedures as stated by most of the respondents:
It prevented early diagnosis. There were serious
problems ranging from the disruption of some ongoing
treatments to not taking or cutting some medications.
(5, rare disease, muscular, patient).
The diagnosis of rare diseases is a very difficult, time‐consuming
process for patients. It requires consultations with different physi-
cians and several medical tests and procedures. Early diagnosis is
important for every illness. Delayed diagnosis undermines successful
treatment procedures, reduces the quality of life and might decrease
life expectancy. The following quote emphasises the importance of
early diagnosis:
Early diagnosis of muscle diseases is very valuable.
The earlier the patient can be diagnosed, the sooner
the patient has the chance to start treatment and the
better chance of living a quality life. […] The diagnosis
process of many patients was disrupted.
(5, rare disease, muscular, patient).
Respondents reported that some physicians cancelled or post-
poned appointments with their patients if they worked at hospitals
with high numbers of patients with COVID‐19. In these cases, pa-
tients felt that physicians had made calculations of the costs and
benefits in favour of COVID‐oriented services, and away from
chronic patients, as stated by a respondent:
Some of the doctors postponed the treatments if
COVID‐19 cases were many in the hospital where
they [patients] went. They [doctors] postponed
those which are not urgent. This postponement has
negative effects on treatment. After all, it does not
show the same effect with the treatment taken in
time, but of course… The doctors decided against it as
benefit and harm.
(9, chronic, cancer, neither patient nor a patient
relative).
However, in some cases, there were barriers to access because
of cancelled treatments and surgeries, and here, patients could not
access the essential treatment procedures as stated by two re-
spondents from two different patient groups:
There were difficulties in accessing physiotherapy
since physiotherapy and rehabilitation centres
were closed for a long time, their [the patients']
physiotherapy was disrupted.
(5, rare disease, muscular, patient).
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There are supervised injection services for spinal
muscular atrophy (SMA) patients. They could not
reach them as they turned into pandemic hospitals;
they did not have the chance to obtain the medication
in those centres.
(5, rare disease, muscular, patient).
The operations of our patients, whose colostomy bags
were opened and whose intestines had to be taken
back in, were postponed because it was not urgent.
(8A, rare disease, neurologic, patient).
As the above quotes demonstrate, some patients did not have
the chance to access the essential treatments and surgeries because
of cancelled treatment and surgeries. For instance, physiotherapy
services play a role for patients with muscular diseases in reducing
the progression of the disease and improving their health. Inability to
access these services can reduce the well‐being of the patients and
has the potential to threaten their health status.5,12
5.2 | Lack of clinical information, uncertainty
and fear
The beginning of the epidemic was characterised by the lack of ac-
curate clinical information and uncertainty about the pandemic, ac-
cess to healthcare services and health risks introduced with infection
by the SARS‐CoV‐2 virus, which resulted in anxiety and fear among
patients about their health. All participants expressed fear caused by
the lack of information and the risk of contact with the virus. The
uncertainty about the pandemic and the risk of contamination dis-
rupted treatment procedures for some patients:
Most of the patients could not go [to the hospitals]
because they were afraid and anxious because of the
uncertainty, especially in the first period. So, the
treatment of our patient group was seriously
disrupted, especially in the first half of the pandemic.
(1, rare disease, metabolic, patient relative).
Uncertainty and fear around the patients did not only disrupt
their treatment but also aggravated their health problems because of
the increasing anxiety. A respondent who is also a patient stated that
attacks caused by their disease had become more frequent during
the pandemic:
Most of the patients had more attacks because of this
uncertainty, their situation at home and their stress.
(4, rare disease, metabolic, patient).
To illustrate the seriousness of the situation, the participant gave an
example of their attacks:
My attacks became more frequent. For example, I
am having two attacks a week or every week.
Normally, I used to have my attacks every six
months, every four or five months.
(4, rare disease, metabolic, patient).
The patient experiences narrated by this participant showed
that even with their worsening health, the patients were not able
to receive immediate treatment because of the fear of going to a
hospital and getting infected with COVID‐19.
Participants in the research said that increasing the avail-
ability of information and new scientific research on COVID‐19
and specific patient groups had contributed to reducing un-
certainties, resulting in the alleviation of anxiety and fear:
The scientific studies have also relieved those liv-
ing with HIV a little bit because these scientific
studies say, HIV+ people with sufficient CD4 have
the same risk of being infected with COVID‐19
compared to HIV−. So, what does a person with a
sufficient level of CD4 mean? If the person is di-
agnosed with HIV and receives proper treatment,
the CD4 count – the immune cell count – is suffi-
cient, this person has at the same risk as people
without HIV. These studies relieved our patients.
(3, chronic disease, infectious, neither patient nor a
patient relative).
Narrating the experiences of patients with HIV, the above
quote illustrates the potential of reliable scientific information to
reduce the widespread anxiety and fear among patients.
5.3 | Facilitated access to prescribed medicine
To reduce the workload of physicians and shift the human re-
sources to pandemic‐oriented care, the SSI extended the period
of repeat prescription reports, which enabled patients to receive
their regular medications from pharmacies without seeing their
doctors if it was not necessary. For all patient groups who par-
ticipated in this study, this was seen as a positive development,
since it reduced their risk of contracting COVID‐19:
This is a valuable thing indeed. It was really a good
thing to extend the report for up to six months, and
the patients having access to their medicines
without going to the doctor to prescribe their
medicines.
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(5, rare disease, muscular, patient).
Despite the consensus in the sample about the benefits of fa-
cilitated access to prescribed medications, some respondents sug-
gested that it is not a viable option, since medication intakes must be
monitored for the health outcomes of the patients:
Now there is no need for a prescription, patients can
go to the pharmacy and buy the medicines directly as
stated in the circular. But, as I have just said, they do
not go to the physician just to get medication. How
did that drug affect the body, how many viruses are
there in the body, how are the blood values, other
additional drugs the patient takes…? Because why are
they [the doctors] visited every three months or every
six months? The drug may not be working at all. The
doctor is constantly observing the patient, they can
change the medication. Some of our patients use only
one pill a day, some of our patients use two or three
pills in certain combinations. Frankly, that's why we
don't think it is a very sustainable thing to have a
prescription without seeing a doctor. Eventually, they
should have these tests and examinations done more
healthily.
(3, chronic disease, infectious, neither patient nor a
patient relative).
As has been identified elsewhere,12 this respondent argues that
the treatment process of chronic and rare diseases requires routine
consultations and medical tests to ensure that the treatment is going
well. While the extension of repeated prescription reports reduces
the number of hospital visits, patients identified a need to see their
doctors in some cases.
5.4 | Ongoing informal communication with
doctors
Patients with chronic or rare diseases in Turkey had close relation-
ships with their doctors due to the long‐term communication that
their health condition requires. During the interviews, respondents
repeatedly talked about how the doctors communicated with the
patients, especially at the beginning of the pandemic:
During this pandemic process those [the doctors] who
advised us, especially professors from the medical
school, frequently held Zoom meetings or live
broadcasts from Instagram. The professors gathered,
some of them from the paediatrics department, some
from others… We all tried to get together at noon or
in the evening, at a common time and ask questions
quickly.
(4, rare disease, metabolic, patient).
The above quote shows that the virtual meetings arranged by
physicians helped patients to obtain information about the pandemic
and disease‐specific issues. Those meetings were especially im-
portant considering the anxiety and fear caused by a lack of in-
formation. However, the information provided by the doctors was
not enough at the beginning of the pandemic, since the doctors were
also facing uncertainty:
Researcher: Do you think that the information pro-
vided by the doctors was helpful to overcome the
uncertainty during the pandemic?
Participant: Of course it wasn't since they were also in
this uncertainty. So, there wasn't a clear picture nei-
ther for the patients nor the doctors, but they did
their best to take action not to harm their patients.
(9, chronic, cancer, neither patient nor a patient
relative).
The above quote shows that physicians also faced difficulties in
providing accurate information to their patients. However, under the
guidance of their medical expertise, they provided the best available
information to their patients to reduce their uncertainties and fear.
6 | DISCUSSION
The restructuring of healthcare systems to address the COVID‐19
pandemic has affected the delivery of clinical services to patients
who do not have COVID‐19. The findings of this study are in line
with the literature on the obstacles caused by the pandemic for
patients with chronic or rare diseases. This study provides a patient
perspective that underscores that access problems experienced by
the patients during the pandemic are a complex mix of factors in-
cluding shortages and physical barriers, but also perceptions of
barriers. Patients' individual experiences with the pandemic, their
health situation and perceived contamination risk also shaped their
access to healthcare services.
The results suggest that the regulations introduced by the MoH
to address the challenges caused by the pandemic created problems
in access to routine and emergency health services. Patients who
needed to consult some specialities such as infectious diseases and
pulmonary medicine consultants who accept COVID‐19 patients
were not able to see their doctors. The cancelled or postponed di-
agnosis procedures involve the risk of worsening the health status of
the patients. For instance, considering the rapid deterioration of
patients with SMA without appropriate treatment, the inability to
access needed care might become life‐threatening. The lack of in-
formation and uncertainty at the beginning of the pandemic resulted
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in anxiety and fear among the patients, which was reduced with the
availability of accurate, scientific information in later months. How-
ever, even when the services were available, patients were sceptical
about face‐to‐face consultations because of the fear of contamina-
tion. Some hospitals and physicians took measures to isolate some
departments from COVID‐19 patients. However, these measures
were not enough, since COVID‐19 is a communicable disease,
causing the fear of contact. The extension of repeat prescriptions by
the SSI was considered a very positive development that made the
lives of patients with chronic and rare diseases easier, reducing their
risk of contact with the virus. However, this regulation is not con-
sidered a viable long‐term solution since the treatment procedure
must be regularly monitored.
The article raises questions about Turkey's ability to provide
access to healthcare services for all citizens as a country with
UHC. The focus on and prioritisation of the needs of patients af-
fected by the pandemic caused disruptions in the continuum of
care for some patients with chronic or rare diseases as the findings
of this study demonstrate. The Minister of Health stated that
Turkey has managed the pandemic successfully with its robust
healthcare system,30 with the transformation of all high‐capacity
hospitals into pandemic hospitals. However, the findings of this
study identify access problems that have been shaped by the
multidimensional nature of the healthcare decision‐making pro-
cess. The Turkish case shows that physicians took initiatives to
cancel or postpone appointments for high‐risk chronic patients
until they could ensure safer healthcare provision in cooperation
with hospitals they work at. While these decisions were in line
with WHO guidance,7 they were not planned by the MoH and not
supported by other mechanisms such as better information pro-
vision, introduction of telehealth or online services and creation of
self‐management and monitoring plans. The lack of these support
mechanisms resulted in uncertainty for patients, causing anxiety
about their healthcare situations, and some patients refrained
from going to the hospitals even on an urgent basis. Therefore, the
findings of this study suggest that the decision‐making process for
cancellations or postponements was multi‐layered, shaped by
physicians' initiatives and patients' individual experiences with the
pandemic. Access problems experienced by patients were a com-
plex mix of factors including shortages and physical barriers, but
also perceptions of barriers.
POs can provide insights on disease‐specific experiences and
problems that are very valuable to improve access to healthcare
services to achieve the UHC target. Considering the access problems
for patients with chronic and rare diseases at the beginning of the
pandemic, POs could have contributed to the decision‐making pro-
cess with their knowledge of disease‐specific patient needs. Hence,
this article suggests that decision‐making authorities should consult
POs to gather information on different needs of patient groups in
times of health crises.
This article suggests that the lack of structural policies addres-
sing all dimensions of healthcare systems to ensure access to care for
all citizens characterised the pandemic experience for patients who
did not have COVID‐19. The complex challenges introduced by the
pandemic in Turkey's healthcare system and its pandemic‐oriented
restructuring interrupted citizens' healthcare rights. Considering the
coexistence of different needs and priorities within the same
healthcare system, the findings of this study lead to the question of
whether it is possible to ensure every citizen's access to healthcare
services during an acute pandemic response. Further research must
be conducted to explore this question to address these multi-
dimensional problems caused by the COVID‐19 pandemic and de-
velop policy alternatives for future health system challenges. This
article concludes by underscoring the potential contribution of POs
to healthcare systems during health crises with their expertise on
patient experiences.
ACKNOWLEDGEMENTS
The author would like to thank Prof. Liz Richardson and Dr. Jonathan
Hammond for their valuable comments, and Dr. Volkan Yilmaz for his
feedback on the research design.
CONFLICT OF INTEREST
The author declares that there is no conflict of interest.
DATA AVAILABILITY STATEMENT





1. Farrell TW, Francis L, Brown T, et al. Rationing limited healthcare
resources in the COVID‐19 era and beyond: ethical considerations
regarding older adults. J Am Geriatr Soc. 2020;68(6):1143‐1149.
https://doi.org/10.1111/jgs.16539
2. Al‐Tabba' A, Al‐Hussaini M, Mansour R, Sultan H, Abdel‐Razeq H,
Mansour A. Ethical considerations for treating cancer patients
during the SARS‐CoV‐2 virus crisis: to treat or not to treat? A lit-
erature review and perspective from a cancer center in low‐middle
income country. Front Med. 2020;7(October):1‐7. https://doi.org/10.
3389/fmed.2020.561168
3. World Health Organization. The impact of the COVID‐19 pandemic on
noncommunicable disease resources and services: results of a rapid
assessment. 2020. https://www.who.int/teams/noncommunicable-
diseases/covid-19. Accessed February 16, 2021.
4. Vogt KS, Ho SK. Rare diseases in the time of COVID‐19: once for-
gotten, always forgotten? The BMJ [The BMJ Opinion]. 2020. https://
blogs.bmj.com/bmj/2020/09/20/rare-diseases-in-the-time-of-covid-19-
once-forgotten-always-forgotten/. Accessed February 16, 2021.
5. Rosenbaum L. Medicine and society the untold toll—the pandemic' s
effects on patients without COVID‐19. N Engl J Med. 2020;382(24):
2368‐2371.
6. von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder:
a systematic review of the qualitative literature. Mol Genet Genomic
Med. 2017;5(6):758‐773. https://doi.org/10.1002/mgg3.315
7. World Health Organization. COVID‐19: operational guidance for




8. World Health Organization. Maintaining essential health services: op-
erational guidance for the COVID‐19 Context: Interim Guidance. World
Health Organization. 2020.
9. Navarro V. The consequences of neoliberalism in the current
pandemic. Int J Health Serv. 2020;50(3):271‐275. https://doi.org/
10.1177/0020731420925449
10. De Ceukelaire W, Bodini C. We need strong public health care to
contain the global corona pandemic. Int J Health Serv. 2020;50(3):
276‐277.
11. World Health Organization. Universal health coverage. 2021.
https://www.who.int/health-topics/universal-health-coverage#tab=
tab_1. Accessed February 23, 2021.
12. Halley MC, Stanley T, Maturi J, et al. “It seems like COVID‐19 now is
the only disease present on Earth”: living with a rare or undiagnosed
disease during the COVID‐19 pandemic. Genet Med. 2021;23:837‐
844. https://doi.org/10.1038/s41436-020-01069-7
13. Chung CC, Wong WH, Fung JL, Hong Kong RD, Chung BH. Impact of
COVID‐19 pandemic on patients with rare disease in Hong Kong. Eur
J Med Genet. 2020;63(12):104062. https://doi.org/10.1016/j.ejmg.2020.
104062
14. Chudasama YV, Gillies CL, Zaccardi F, et al. Impact of COVID‐19 on
routine care for chronic diseases: a global survey of views from
healthcare professionals. Diabetes Metab Syndr Clin Res Rev. 2020;
14(5):965‐967. https://doi.org/10.1016/j.dsx.2020.06.042
15. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G.
Delayed access or provision of care in Italy resulting from fear of
COVID‐19. Lancet Child Adolesc Health. 2020;4(5):e10‐e11. https://
doi.org/10.1016/S2352-4642(20)30108-5
16. Qiao S, Yang X, Sun S, et al. Challenges to HIV service delivery and
the impacts on patient care during COVID‐19: perspective of HIV
care providers in Guangxi, China. AIDS Care. 2020;33(5):1‐7. https://
doi.org/10.1080/09540121.2020.1849532
17. Farha S. COVID‐19 and pulmonary hypertension. Cleve Clin J Med.
2020;87(5):1‐3. https://doi.org/10.3949/CCJM.87A.CCC021
18. Wingrove C, Ferrier L, James C, Wang S. The impact of COVID‐19
on hepatitis elimination. Lancet Gastroenterol Hepatol. 2020;5(9):
792‐794. https://doi.org/10.1016/S2468-1253(20)30238-7
19. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID‐19 on global
HCV elimination efforts. J Hepatol. 2021;74(1):31‐36. https://doi.
org/10.1016/j.jhep.2020.07.042
20. Koffman J, Gross J, Etkind SN, Selman L. Uncertainty and
COVID‐19: how are we to respond? J R Soc Med. 2020;113(6):
211‐216. https://doi.org/10.1177/0141076820930665
21. Young AM, Ashbury FD, Schapira L, Scotté F, Ripamonti CI, Olver IN.
Uncertainty upon uncertainty: supportive care for cancer and
COVID‐19. Support Care Cancer. 2020;28(9):4001‐4004. https://doi.org/
10.1007/s00520-020-05604-9
22. Umucu E, Lee B. Examining the impact of COVID‐19 on stress and
coping strategies in individuals with disabilities and chronic condi-
tions. Rehabil Psychol. 2020;65(3):193‐198. https://doi.org/10.1037/
rep0000328
23. Webster P. Virtual health care in the era of COVID‐19. Lancet.
2020;395(10231):1180‐1181. https://doi.org/10.1016/S0140-6736
(20)30818-7
24. Ortega G, Rodriguez JA, Maurer LR, et al. Telemedicine,
COVID‐19, and disparities: policy implications. Heal Policy Technol.
2020;9(3):368‐371. https://doi.org/10.1016/j.hlpt.2020.08.001
25. World Bank. Turkey. 2021. https://data.worldbank.org/country/
turkey. Accessed May 3, 2021.
26. Agartan TI. Marketization and universalism: crafting the right
balance in the Turkish healthcare system. Curr Sociol. 2012;
60(4):456‐471. https://doi.org/10.1177/0011392112438331
27. Yilmaz V. The Politics of Healthcare Reform in Turkey. Cham,
Switzerland: Palgrave Macmillan; 2017. https://doi.org/10.
1007/978-3-319-53667-5
28. The Ministry of Health. Sağlık İstatistikleri Yıllığı 2018 Haber
Bülteni (Health Statistics Yearbook 2018 Newsletter). 2019.
29. OECD. Beyond containment: Health systems responses to COVID‐19
in the OECD 2020. https://read.oecd-ilibrary.org/view/?ref=119_
119689-ud5comtf84%26title=Beyond_Containment:Health_systems_
responses_to_COVID-19_in_the_OECD. Accessed February 15, 2021.
30. Koca F. Turkey's management of Covid‐19: measures and stra-
tegies of health policies. Insight Turkey. 2020;22(Summer 2020):
55‐65.
31. The Ministry of Health. Circulation on Pandemic Hospitals. The
Ministry of Health. 2020.
32. OECD. Health at a Glance 2019. Paris: OECD Publishing; 2019.
https://doi.org/10.1787/4dd50c09-en
33. Istanbul Medical Chamber. Hekimler ve Sağlık Çalışanlarının
Enerjisi ve Sabrı Tükeniyor (Physicians and Healthcare Profes-
sionals Are Burning Out). 2020. https://www.istabip.org.tr/
koronavirus/Haberler/6061/hekimler-ve-saglik-calisanlarinin-
enerjisi-ve-sabri-tukeniyor. Accessed June 12, 2021.
34. Yerlikaya H. COVID‐19 Pandemisi 9. Ay Değerlendirme Ra-
poru. Bizi Bekleyen Kanser Pandemisi. Turkish Medical Asso-
ciation. 2020.
35. Ari I Kanser pandemisi kapıda! (Cancer pandemic is at the
door!). Birgün. https://www.birgun.net/haber/kanser-pandemisi-
kapida-326405. Published December 13, 2020. Accessed Feb-
ruary 16, 2021.
36. Simsek D, Birgün. Covid‐19 korkusu erken tanıyı geciktirdi (Fear
of COVID‐19 delayed the early diagnosis). 2021. https://www.
birgun.net/haber/covid-19-korkusu-erken-taniyi-geciktirdi-
334201. Accessed February 16, 2021.
37. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res
Psychol. 2006;3(2):77‐101. https://doi.org/10.1191/1478088706qp06
3oa
How to cite this article: Aktas P. Chronic and rare disease
patients' access to healthcare services during a health
crisis: The example of the COVID‐19 pandemic
in Turkey. Health Expect. 2021;1‐9.
https://doi.org/10.1111/hex.13321
AKTAS | 9
